Advertisement
UK markets close in 6 hours 14 minutes
  • FTSE 100

    8,106.06
    +27.20 (+0.34%)
     
  • FTSE 250

    19,808.38
    +206.40 (+1.05%)
     
  • AIM

    756.23
    +3.11 (+0.41%)
     
  • GBP/EUR

    1.1654
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2520
    +0.0009 (+0.07%)
     
  • Bitcoin GBP

    51,455.62
    +268.96 (+0.53%)
     
  • CMC Crypto 200

    1,389.58
    -6.95 (-0.50%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.61
    +0.04 (+0.05%)
     
  • GOLD FUTURES

    2,360.80
    +18.30 (+0.78%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,047.38
    +130.10 (+0.73%)
     
  • CAC 40

    8,037.95
    +21.30 (+0.27%)
     

Surging Earnings Estimates Signal Good News for Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated VRTX focuses on the discovery and commercialization of small molecule drugs that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on VRTX’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Vertex Pharmaceuticals could be a solid choice for investors.

Current Quarter Estimates for VRTX

In the past 30 days, three estimates have gone higher for Vertex Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from $1.34 a share 30 days ago, to $1.77 today, a move of 32.1%.

Current Year Estimates for VRTX

Meanwhile, Vertex Pharmaceuticals’ current year figures are also looking quite promising, with 12 estimates moving higher in the past month, compared to one lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $6.68 per share 30 days ago to $7.57 per share today, an increase of 13.3%.

Vertex Pharmaceuticals Incorporated Price and Consensus

Vertex Pharmaceuticals Incorporated Price and Consensus
Vertex Pharmaceuticals Incorporated Price and Consensus

Vertex Pharmaceuticals Incorporated price-consensus-chart | Vertex Pharmaceuticals Incorporated Quote

ADVERTISEMENT


Bottom Line

The stock has also started to move higher lately, adding 5.1% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research